---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022631"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:39:28.059055+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma reports Q3 2025 net loss of $3.1M; cash $2.6M funds into Q1 2026

## Summary
- Net loss of $3.1M for Q3 2025 improved from $3.4M in Q3 2024.
- Cash and equivalents $2.6M expected to fund operations into Q1 2026.
- R&D expenses fell to $0.6M from $1.3M due to lower production and material costs.
- Phase 1 GTB-3650 trial now in Cohort 4 at 10 µg/kg/day; next update Q1 2026.
- GTB-5550 IND submission for B7H3 tumors expected late Dec 2025 or Jan 2026.

## SEC filing metadata
- accession: 0001493152-25-022631
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315225022631/0001493152-25-022631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315225022631/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022631
- JSON: https://secwatch.observer/filing/0001493152-25-022631.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.